Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease

evoke and evoke+ are the only large-scale randomized controlled trials (RCTs) investigating the longer-term efficacy and safety of semaglutide in early AD.Baseline characteristics reflect a varied, global population.The trials' primary readouts are expected in the second half of 2025.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia Translational Research & Clinical Interventions
Published
2026-01-01
DOI
https://doi.org/10.1002/trc2.70200
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease

Lars Bardtrum, Charlotte T. Hansen, Rose Jeppesen, J. R. Cummings et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions
Diabetes Treatment and Management
article

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease

Lars Bardtrum, Charlotte T. Hansen, Rose Jeppesen, J. R. Cummings, Henrik Zetterberg, Teresa León Colombo, Mary Sano, Alireza Atri, Howard H. Feldman, Peter Johannsen, Philip Scheltens
article en

Abstract

evoke and evoke+ are the only large-scale randomized controlled trials (RCTs) investigating the longer-term efficacy and safety of semaglutide in early AD.Baseline characteristics reflect a varied, global population.The trials' primary readouts are expected in the second half of 2025.

Alzheimer s & Dementia Translational Research & Clinical InterventionsVol. 12(1)
Alzheimer's Association (US), Brigham and Women's Hospital (US), University of Nevada, Las Vegas (US), Harvard University (US), Novo Nordisk (Denmark) (DK), Sahlgrenska University Hospital (SE), Alzheimer’s Disease Neuroimaging Initiative (US), Amsterdam Neuroscience (NL), Institute for Neurodegenerative Disorders (US), James J. Peters VA Medical Center (US), UK Dementia Research Institute (GB), Banner Sun Health Research Institute (US), National Hospital for Neurology and Neurosurgery (GB), Banner Alzheimer’s Institute, University College London (GB), Amsterdam University of Applied Sciences (NL), Vrije Universiteit Amsterdam (NL), University of Gothenburg (SE), Icahn School of Medicine at Mount Sinai (US)
Novo Nordisk
Openalex Percentile: Top 92%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease — Lars Bardtrum, Charlotte T. Hansen, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions (2026) | TGRS Research Map | TGRS